Kasturba Medical College, Mangalore, Karnataka 575001, India.
SUNY Downstate College of Medicine, Brooklyn NY, 11225.
Cancer Treat Res Commun. 2021;26:100278. doi: 10.1016/j.ctarc.2020.100278. Epub 2020 Dec 11.
The significant physical and emotional effects of chemotherapy-induced nausea and vomiting (CINV) are experienced by cancer patients. Severe symptoms decrease the patient's quality of life and potentially deters further treatment. The five main forms of CINV (i.e., acute, delayed, anticipatory, breakthrough, and refractory) require different treatment regimens, which often include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Despite a significant amount of research and development of antiemetic agents, management of CINV remains a great challenge with many needs waiting to be adequately addressed, such as controlling non-acute CINV, developing appropriate CINV treatment protocols for multiple-day chemotherapy patients, and providing options for those prone to CINV despite treatment. Further research is required to optimize CINV management for these patients.
化疗引起的恶心和呕吐(CINV)会给癌症患者带来显著的身体和情绪影响。严重的症状会降低患者的生活质量,并可能阻碍进一步的治疗。CINV 有五种主要形式(即急性、延迟性、预期性、突破性和难治性),需要不同的治疗方案,通常包括 5-HT3 受体拮抗剂、NK1 受体拮抗剂和皮质类固醇。尽管对抗恶心药物进行了大量的研究和开发,但 CINV 的管理仍然是一个巨大的挑战,有许多需求亟待充分解决,例如控制非急性 CINV、为多日化疗患者制定适当的 CINV 治疗方案,以及为那些尽管接受治疗仍易发生 CINV 的患者提供选择。需要进一步的研究来优化这些患者的 CINV 管理。